Ocuphire Pharma Current Ratio 2010-2024 | IRD
Ocuphire Pharma current ratio from 2010 to 2024. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| Ocuphire Pharma Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2024-06-30 |
$0.05B |
$0.00B |
10.68 |
| 2024-03-31 |
$0.05B |
$0.01B |
8.96 |
| 2023-12-31 |
$0.05B |
$0.00B |
13.35 |
| 2023-09-30 |
$0.05B |
$0.00B |
13.86 |
| 2023-06-30 |
$0.04B |
$0.01B |
7.54 |
| 2023-03-31 |
$0.05B |
$0.00B |
10.93 |
| 2022-12-31 |
$0.05B |
$0.00B |
17.79 |
| 2022-09-30 |
$0.02B |
$0.00B |
5.41 |
| 2022-06-30 |
$0.02B |
$0.00B |
5.42 |
| 2022-03-31 |
$0.02B |
$0.00B |
6.37 |
| 2021-12-31 |
$0.03B |
$0.00B |
6.76 |
| 2021-09-30 |
$0.02B |
$0.00B |
8.79 |
| 2021-06-30 |
$0.03B |
$0.00B |
9.35 |
| 2021-03-31 |
$0.01B |
$0.00B |
5.24 |
| 2020-12-31 |
$0.02B |
$0.00B |
5.55 |
| 2020-09-30 |
$0.01B |
$0.00B |
2.88 |
| 2020-06-30 |
$0.01B |
$0.00B |
3.37 |
| 2020-03-31 |
$0.01B |
$0.00B |
5.70 |
| 2019-12-31 |
$0.00B |
$0.01B |
0.19 |
| 2019-09-30 |
$0.02B |
$0.00B |
4.88 |
| 2019-06-30 |
$0.02B |
$0.00B |
4.87 |
| 2019-03-31 |
$0.02B |
$0.00B |
7.57 |
| 2018-12-31 |
$0.02B |
$0.00B |
5.04 |
| 2018-09-30 |
$0.01B |
$0.00B |
4.12 |
| 2018-06-30 |
$0.02B |
$0.00B |
5.36 |
| 2018-03-31 |
$0.02B |
$0.00B |
7.35 |
| 2017-12-31 |
$0.03B |
$0.00B |
8.70 |
| 2017-09-30 |
$0.02B |
$0.00B |
10.47 |
| 2017-06-30 |
$0.03B |
$0.00B |
14.59 |
| 2017-03-31 |
$0.02B |
$0.00B |
11.35 |
| 2016-12-31 |
$0.02B |
$0.00B |
11.12 |
| 2016-09-30 |
$0.02B |
$0.00B |
12.66 |
| 2016-06-30 |
$0.02B |
$0.00B |
11.36 |
| 2016-03-31 |
$0.03B |
$0.00B |
7.74 |
| 2015-12-31 |
$0.03B |
$0.00B |
9.27 |
| 2015-09-30 |
$0.02B |
$0.00B |
7.08 |
| 2015-06-30 |
$0.03B |
$0.00B |
8.60 |
| 2015-03-31 |
$0.03B |
$0.00B |
11.05 |
| 2014-12-31 |
$0.03B |
$0.00B |
13.59 |
| 2014-09-30 |
$0.04B |
$0.00B |
21.06 |
| 2014-06-30 |
$0.04B |
$0.00B |
25.40 |
| 2014-03-31 |
$0.04B |
$0.00B |
46.56 |
| 2013-12-31 |
$0.02B |
$0.00B |
20.66 |
| 2013-09-30 |
$0.02B |
$0.00B |
20.65 |
| 2013-06-30 |
$0.01B |
$0.00B |
16.88 |
| 2013-03-31 |
$0.01B |
$0.00B |
12.65 |
| 2012-12-31 |
$0.01B |
$0.00B |
16.17 |
| 2012-09-30 |
$0.01B |
$0.00B |
8.83 |
| 2012-06-30 |
$0.01B |
$0.00B |
10.01 |
| 2012-03-31 |
$0.01B |
$0.00B |
10.15 |
| 2011-12-31 |
$0.01B |
$0.00B |
10.26 |
| 2011-09-30 |
$0.02B |
$0.00B |
4.01 |
| 2011-06-30 |
$0.02B |
$0.00B |
4.78 |
| 2011-03-31 |
$0.02B |
$0.00B |
8.07 |
| 2010-12-31 |
$0.02B |
$0.00B |
8.61 |
| 2010-09-30 |
$0.02B |
$0.00B |
12.63 |
| 2010-06-30 |
$0.02B |
$0.00B |
11.51 |
| 2010-03-31 |
$0.01B |
$0.00B |
9.10 |
| 2009-12-31 |
$0.01B |
$0.00B |
9.92 |
| 2009-09-30 |
$0.00B |
$0.00B |
9.20 |
| 2009-06-30 |
$0.00B |
$0.00B |
5.75 |
| 2009-03-31 |
$0.00B |
$0.00B |
6.40 |
| Sector |
Industry |
Market Cap |
Revenue |
|
|
$0.000B |
$0.000B |
|
Ocuphire Pharma Inc. is a clinical-stage ophthalmic biopharmaceutical company. It is focused on developing and commercializing therapies for the treatment of several eye disorders. The company's product pipeline includes Nyxol Eye Drops(R) and APX3330. Ocuphire Pharma Inc., formerly known as Rexahn Pharmaceuticals Inc., is based in FARMINGTON HILLS, Mich.
|
